ArticleNature communications2024
Converging and evolving immuno-genomic routes toward immune escape in breast cancer.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.Cancer cell · 2026Article
- Spatially resolved T cell receptor diversity mapping uncovers variability of the cancer immune microenvironment.EBioMedicine · 2026Article
- Tracking response to neoadjuvant systemic therapy through circulating tumor DNA analysis in breast cancer.NPJ breast cancer · 2026Article
- Review
- Distinct evolutionary patterns of tumour-immune escape and elimination determined by extracellular matrix architectures.Journal of the Royal Society, Interface · 2025Article
- Variation in bulk RNA-seq and estimated cell type proportion using deconvolution when comparing pancreatic cancer samples within the same individual.medRxiv : the preprint server for health sciences · 2025Article
- CD4Science advances · 2025Article
- Bulk RNA-seq deconvolution heterogeneity across paired pancreatic cancer human samples.Frontiers in genetics · 2025Article
- Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation.Nature immunology · 2024Article
- Single-cell and spatial omics unravel the spatiotemporal biology of tumour border invasion and haematogenous metastasis.Clinical and translational medicine · 2024Review
- Discovery of oxazine-linked pyrimidine as an inhibitor of breast cancer growth and metastasis by abrogating NF-κB activation.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 9 institutions in 4 countries.
Funding
Abstract
The interactions between tumor and immune cells along the course of breast cancer progression remain largely unknown. Here, we extensively characterize multiple sequential and parallel multiregion tumor and blood specimens of an index patient and a cohort of metastatic triple-negative breast cancers. We demonstrate that a continuous increase in tumor genomic heterogeneity and distinct molecular clocks correlated with resistance to treatment, eventually allowing tumors to escape from immune control. TCR repertoire loses diversity over time, leading to convergent evolution as breast cancer progresses. Although mixed populations of effector memory and cytotoxic single T cells coexist in the peripheral blood, defects in the antigen presentation machinery coupled with subdued T cell recruitment into metastases are observed, indicating a potent immune avoidance microenvironment not compatible with an effective antitumor response in lethal metastatic disease. Our results demonstrate that the immune responses against cancer are not static, but rather follow dynamic processes that match cancer genomic progression, illustrating the complex nature of tumor and immune cell interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.